Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03659422 |
Recruitment Status :
Withdrawn
(not funded)
First Posted : September 6, 2018
Last Update Posted : June 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diet Modification Amyotrophic Lateral Sclerosis | Other: Modified Paleolithic diet | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Dietary Approach to Improving QoL in ALS |
Estimated Study Start Date : | July 1, 2019 |
Estimated Primary Completion Date : | July 1, 2021 |
Estimated Study Completion Date : | July 1, 2021 |

Arm | Intervention/treatment |
---|---|
Intervention Arm
Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
|
Other: Modified Paleolithic diet
The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods. |
- Change in total body weight from baseline over 12 weeks. [ Time Frame: 12 weeks ]body weight (kilograms)
- Change in Body Mass Index from baseline over 12 weeks. [ Time Frame: 12 weeks ]body weight (in kilograms) divided by height square (in meters)
- change in fat mass (in kilograms) from baseline over 12 weeks [ Time Frame: 12 weeks ]Bio-electrical impedance measurement of body composition
- change in fat-free mass (in kilograms) from baseline over 12 weeks [ Time Frame: 12 weeks ]Bio-electrical impedance measurement of body composition
- change in motor function over 12 weeks [ Time Frame: 12 weeks ]Grip strength
- change in breathing function over 12 weeks [ Time Frame: 12 weeks ]Forced Expiratory Volume
- Change in fatigue level [ Time Frame: 12 weeks ]Fatigue Severity Scale is used. scale has 9 questions, each could range from 1 to 7. Sum responses and divide by number of items for scale score. Higher score indicates more disability.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite ALS (using the revised El Escorial Criteria)
- Ability to prepare, or have prepared for them, home-cooked meals
- Age between 18 and 80 years
- Followed by ALS clinic at the University of Iowa
- Willingness to adopt the study diet
Exclusion Criteria:
- Clinically significant liver, kidney, or heart disease
- Taking insulin or Coumadin
- Ventilator dependence
- Psychiatric disorder making dietary compliance difficult (e.g. schizophrenia)
- Unwillingness to have blood specimens collected
- Dysphagia present
- Greater than two years since onset of ALS symptoms

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03659422
Principal Investigator: | Terry L Wahls, MD | University of Iowa |
Responsible Party: | Terry L. Wahls, Clinical Professor of Medicine, Principal Investigator, University of Iowa |
ClinicalTrials.gov Identifier: | NCT03659422 |
Other Study ID Numbers: |
201802746 |
First Posted: | September 6, 2018 Key Record Dates |
Last Update Posted: | June 14, 2019 |
Last Verified: | June 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |